F-box and leucine rich repeat protein 5Genealiases: CC2D2A-AS1 · FBL4 · FBL5 · FLR1
Q-omics provides the consensus-scored FBXL5 profile across patient tissues and cancer cell-line models. FBXL5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXL5 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, FBXL5 RNA expression shows 20,497 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where FBXL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL5 survival associations across molecular data types. FBXL5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL5 RNA expression–survival associations across cancer types. High FBXL5 expression shows favorable associations in KIRC, KIRP, SKCM, MESO, ESCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXL5 RNA expression.
This table summarizes FBXL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL5 shows lower tumor expression in THCA, KICH, LUAD, COAD and BLCA and higher tumor expression in KIRC. The THCA box plot shows higher FBXL5 RNA expression in normal versus tumor tissue (log2 FC = −1.537, t-test p < 0.001).
This table shows molecular features associated with FBXL5 in patient tissues and cancer cell lines. In patient samples, FBXL5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
